Sunday 18 October 2026
Export PALI’s income statement to Excel — free account
Palisade Bio, Inc.
PALI Healthcare Biotechnology
Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00. In the quarter to June 2026, revenue grew 19,900.0%, EPS grew 91.4% and free cash flow fell 318.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.41
0.13
−8.44%
Follow PALI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (51.37%) | (36.40%) | (24.52%) | (228.73%) |
+8 more TTM periods Free account |
|
| (47.68%) | (34.13%) | (23.11%) | (137.67%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(26.18%) | (18.92%) | (12.95%) | (335.10%) | |
Average Days of Receivables |
241.72 | — | — | — | |
Free Cash Flow per Share |
(0.09) | (0.06) | (0.19) | (1.35) | |
Free Cash Flow |
(18.19) | (12.40) | (10.85) | (10.08) | |
| Other line items | |||||
Cash ROIC |
(7.37%) | (4.77%) | (4.12%) | (116.58%) | |
Accounts Receivable Turnover |
0.78 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,829.67% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,918.54% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
1,708.48% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | (2,649.40) | (1,805.60) | (1,041.55) | |
Operating CF/Net income |
0.57 | 0.51 | 0.65 | 0.90 | |
Depreciation/Fixed assets |
— | — | 0.00 | 0.00 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.09) | (0.06) | (0.19) | (1.35) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates